Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Boehringer Ingelheim
Mallinckrodt
Dow
McKinsey

Last Updated: January 29, 2022

Volunteer for clinical trials for envarsus xr at ClinicalTrialExchange

DrugPatentWatch Database Preview

envarsus xr Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Envarsus Xr patents expire, and what generic alternatives are available?

Envarsus Xr is a drug marketed by Veloxis Pharms Inc and is included in one NDA. There are twenty patents protecting this drug.

This drug has sixty-six patent family members in twenty-four countries.

The generic ingredient in ENVARSUS XR is tacrolimus. There are twenty drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the tacrolimus profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Envarsus Xr

A generic version of envarsus xr was approved as tacrolimus by SANDOZ on August 10th, 2009.

  Try it Free

US Patents and Regulatory Information for envarsus xr

envarsus xr is protected by twenty-six US patents and one FDA Regulatory Exclusivity.

Patents protecting envarsus xr

Stabilized tacrolimus composition
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Solid dispersions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS

Solid dispersions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT

Tacrolimus for improved treatment of transplant patients
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT

Tacrolimus for improved treatment of transplant patients
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS

Tacrolimus for improved treatment of transplant patients
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT

Tacrolimus for improved treatment of transplant patients
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS

Solid dispersions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Solid dispersions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION

Modified release compositions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION

Modified release compositions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Modified release compositions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Modified release compositions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Modified release compositions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION

Tacrolimus for improved treatment of transplant patients
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION

Tacrolimus for improved treatment of transplant patients
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS

Tacrolimus for improved treatment of transplant patients
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT

Tacrolimus for improved treatment of transplant patients
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION

Tacrolimus for improved treatment of transplant patients
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT

Tacrolimus for improved treatment of transplant patients
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS

Modified release compositions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION

Modified release compositions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION

Modified release compositions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: PROPHYLAXIS OF ORGAN REJECTION

Stabilized tacrolimus composition
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Modified release compositions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Solid dispersions comprising tacrolimus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

FDA Regulatory Exclusivity protecting envarsus xr

PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY TRANSPLANT PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
Exclusivity Expiration: ⤷  Try it Free

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Veloxis Pharms Inc ENVARSUS XR tacrolimus TABLET, EXTENDED RELEASE;ORAL 206406-002 Jul 10, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Veloxis Pharms Inc ENVARSUS XR tacrolimus TABLET, EXTENDED RELEASE;ORAL 206406-002 Jul 10, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Veloxis Pharms Inc ENVARSUS XR tacrolimus TABLET, EXTENDED RELEASE;ORAL 206406-002 Jul 10, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Veloxis Pharms Inc ENVARSUS XR tacrolimus TABLET, EXTENDED RELEASE;ORAL 206406-003 Jul 10, 2015 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Veloxis Pharms Inc ENVARSUS XR tacrolimus TABLET, EXTENDED RELEASE;ORAL 206406-002 Jul 10, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Moodys
Colorcon
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.